Nartograstim

BeschreibungNartograstim, a highly active mutein of the granulocyte colony-stimulating factor (G-CSF) produced by recombinant technology, was introduced in Japan for the treatment of chemotherapy-induced granulocytopenia, rhabdomyosarcoma and neutropenia associated with infantile acute lymphatic leukemia and infantile aplastic anemia. In mice, nartograstim showed an excellent accelerating effect on rapid recovery from severe leukopenia induced by typical anticancer agents such as mitomycin C and adriamycin. In patients with advanced lung cancer, nartograstim has been reported to produce a significant shortening of the period of neutropenia and an acceleration of neutrophil count recovery. With changes of five amino acids at the N-terminal region of human G-CSF, nartograstim has superior in vivo hematopoietic effects to the intact rhG-CSF due to its higher specific activity to progenitor cells and its improved physicochemical, biological and pharmacokinetic stability.